APA (7th ed.) Citation

Giannelos, N., Nishimwe, M. L., & Lecrenier, N. (2022). Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”. PharmacoEconomics, 40(10), 1011-1012. https://doi.org/10.1007/s40273-022-01184-0

Chicago Style (17th ed.) Citation

Giannelos, Nikolaos, Marie Libérée Nishimwe, and Nicolas Lecrenier. "Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison Between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”." PharmacoEconomics 40, no. 10 (2022): 1011-1012. https://doi.org/10.1007/s40273-022-01184-0.

MLA (9th ed.) Citation

Giannelos, Nikolaos, et al. "Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison Between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”." PharmacoEconomics, vol. 40, no. 10, 2022, pp. 1011-1012, https://doi.org/10.1007/s40273-022-01184-0.